Bilal Abid, MD, MS (@bilalabidmd) 's Twitter Profile
Bilal Abid, MD, MS

@bilalabidmd

Oncologist | Athlete | Lymphoma | Myeloma | Transplant | Cellular Therapy | Infections | #TxID | CMV | Views personal | RT ≠ endorsements

ID: 1111674891097526272

linkhttps://www.medicalsocietymilwaukee.org/News/13182598 calendar_today29-03-2019 17:02:02

1,1K Tweet

638 Followers

598 Following

Jeff Auletta (@jeffauletta) 's Twitter Profile Photo

Check out the 2025 ASTCT CIBMTR Tandem Meetings video and news page! Can't wait to see you next month in Hawaii! youtu.be/WeNS4sNwb-E tandemmeetingsnews.com

Aga Khan University (@akuglobal) 's Twitter Profile Photo

His Highness Prince Karim Al-Hussaini, Aga Khan IV, 49th hereditary Imam of the Shia Ismaili Muslims passed away peacefully in Lisbon on 4 February 2025, aged 88, surrounded by his family. Prince Karim Aga Khan was the founder and chairman of the Aga Khan Development Network.

His Highness Prince Karim Al-Hussaini, Aga Khan IV, 49th hereditary Imam of the Shia Ismaili Muslims passed away peacefully in Lisbon on 4 February 2025, aged 88, surrounded by his family. Prince Karim Aga Khan was the founder and chairman of the Aga Khan Development Network.
Jeff Auletta (@jeffauletta) 's Twitter Profile Photo

Interested in learning more about CIBMTR working communities and CIBMTR in general? Apply for the Page Scholars Program in memory of an incredible colleague, Dr. Kristin Page. #Tandem25

Interested in learning more about <a href="/CIBMTR/">CIBMTR</a> working communities and <a href="/CIBMTR/">CIBMTR</a> in general? Apply for the Page Scholars Program in memory of an incredible colleague, Dr. Kristin Page. #Tandem25
ASTCT (@astct) 's Twitter Profile Photo

“We are going to survive and do the right thing, because doing the right thing is never the wrong thing,” says Dr. Jeff Auletta, followed by applause from attendees. @NMDP

“We are going to survive and do the right thing, because doing the right thing is never the wrong thing,” says Dr. <a href="/JeffAuletta/">Jeff Auletta</a>, followed by applause from attendees. @NMDP
Bilal Abid, MD, MS (@bilalabidmd) 's Twitter Profile Photo

Excited to present on the evolving cell therapy landscape and our early phase work in pipeline later this week. Thanks for the invite, UT San Antonio MD Anderson Cancer Center! mayscc.eventsair.com/panao2025/agen… #CellularTherapy @UTHealthSAMDA #CARTcells #SolidTumors 🧬 💉

Excited to present on the evolving cell therapy landscape and our early phase work in pipeline later this week. Thanks for the invite, UT San Antonio MD Anderson Cancer Center!

mayscc.eventsair.com/panao2025/agen…

#CellularTherapy  @UTHealthSAMDA #CARTcells  #SolidTumors 🧬 💉
Frederick L. Locke (@drfredlocke) 's Twitter Profile Photo

Off-the-shelf CAR-T is here! Our phase 1 trial in Journal of Clinical Oncology shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS ascopubs.org/doi/10.1200/JC…

Off-the-shelf CAR-T is here! Our phase 1 trial in <a href="/JCO_ASCO/">Journal of Clinical Oncology</a> shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL:
🔹42% CR rate with median CR duration 23.1 months
🔹No GVHD, ICANS, or severe CRS
ascopubs.org/doi/10.1200/JC…
OncoDaily (@oncodaily) 's Twitter Profile Photo

Concluded the PANAO 2025 conference - M. Bilal Abid Bilal Abid, MD, MS oncodaily.com/blog/concluded… #Cancer #CancerResearch #PANAO #Medicine #MedEd #MedNews #MedX #Health #Conference #Oncology #OncoDaily

Concluded the PANAO 2025 conference - M. Bilal Abid
<a href="/BilalAbidMD/">Bilal Abid, MD, MS</a> 

oncodaily.com/blog/concluded… 

#Cancer #CancerResearch #PANAO #Medicine #MedEd #MedNews #MedX #Health #Conference #Oncology #OncoDaily
OncoDaily (@oncodaily) 's Twitter Profile Photo

Impact of Disparity – Navigating Treatment Equality in Cancer Care - M. Bilal Abid Bilal Abid, MD, MS oncodaily.com/blog/251256 #Cancer #CancerCare #Podcast #CancerTreatment #MedX #MedNews #MedEd #Medicine #Health #Oncology #OncoDaily

Impact of Disparity – Navigating Treatment Equality in Cancer Care - M. Bilal Abid
<a href="/BilalAbidMD/">Bilal Abid, MD, MS</a> 

oncodaily.com/blog/251256 

#Cancer #CancerCare #Podcast #CancerTreatment #MedX #MedNews #MedEd #Medicine #Health #Oncology #OncoDaily
Bilal Abid, MD, MS (@bilalabidmd) 's Twitter Profile Photo

SCT rounds caring for patients undergoing stem cell transplantation with Dr Issa Khouri - Sunday morning couldn’t get better! #bmtsm #CARTcell #blessed MD Anderson Cancer Center 🩸

SCT rounds caring for patients undergoing stem cell transplantation with Dr Issa Khouri - Sunday morning couldn’t get better! #bmtsm #CARTcell #blessed <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> 🩸
Robert Z. Orlowski (@myeloma_doc) 's Twitter Profile Photo

#Myeloma Paper of the Day: Study of outcomes in myeloma patients undergoing ASCT after suboptimal pretransplant response (<VGPR) finds median PFS & OS were 38.6 (95% confidence interval [CI], 35.9–41.9) months and 103.8 (95% CI, 96.4–113.2) months: onlinelibrary.wiley.com/doi/epdf/10.11…. #mmsm

#Myeloma Paper of the Day: Study of outcomes in myeloma patients undergoing ASCT after suboptimal pretransplant response (&lt;VGPR) finds median PFS &amp; OS were 38.6 (95% confidence interval [CI], 35.9–41.9) months and 103.8 (95% CI, 96.4–113.2) months: onlinelibrary.wiley.com/doi/epdf/10.11…. #mmsm
OncoDaily (@oncodaily) 's Twitter Profile Photo

Myeloma Paper of the Day, March 31st, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Muzaffar Qazilbash Bilal Abid, MD, MS oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MyelomaPaperOfTheDay #MultipleMyeloma

Myeloma Paper of the Day, March 31st, suggested by Robert Orlowski (<a href="/Myeloma_Doc/">Robert Z. Orlowski</a>)
<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/Transplant_Doc/">Muzaffar Qazilbash</a> <a href="/BilalAbidMD/">Bilal Abid, MD, MS</a>

oncodaily.com/science/myelom…

#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MyelomaPaperOfTheDay #MultipleMyeloma
Muzaffar Qazilbash (@transplant_doc) 's Twitter Profile Photo

Outcomes of patients with multiple myeloma undergoing autoSCT with suboptimal pretransplant response. N=1109 with <VGPR to induction. Median PFS/OS: 38.6/103.8 months Bilal Abid, MD, MS #mmsm #bmtsm onlinelibrary.wiley.com/doi/10.1111/bj…

Mostafa Faisal (@mostafafaisal14) 's Twitter Profile Photo

Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response British Journal of Haematology onlinelibrary.wiley.com/doi/10.1111/bj…

OncoDaily (@oncodaily) 's Twitter Profile Photo

Outcomes of NDMM patients who undergo autoHCT after achieving suboptimal response to induction - Bilal Abid, MD, MS oncodaily.com/url/268413 #NDMM #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #AutoHCT

James Wu | 吴简凡 MD (@jamesfanwu) 's Twitter Profile Photo

📜 in Leukemia Journal: “National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients” 🙏🏼 Edward Christopher "Chris" Dee, MD Erin Feliciano, MD, MBA Bilal Abid, MD, MS Dr. Tremblay Dr. Singh #leusm 🔗: nature.com/articles/s4137… Expand for a thread on our paper ⤵️

📜 in <a href="/LeukemiaJnl/">Leukemia Journal</a>: “National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients”

🙏🏼 <a href="/EChrisDee/">Edward Christopher "Chris" Dee, MD</a> <a href="/erin_feliciano/">Erin Feliciano, MD, MBA</a> <a href="/BilalAbidMD/">Bilal Abid, MD, MS</a> Dr. Tremblay Dr. Singh #leusm 

🔗: nature.com/articles/s4137…

Expand for a thread on our paper ⤵️
James Wu | 吴简凡 MD (@jamesfanwu) 's Twitter Profile Photo

We hope this research serves as a catalyst for #global initiatives to strengthen health systems to improve leukemia outcomes. I am honored to have published this work w/ an amazing team Edward Christopher "Chris" Dee, MD Erin Feliciano, MD, MBA Bilal Abid, MD, MS Dr. Tremblay Dr. Singh 🌎🌍🌏 15/x

Oncology News Central (@oncnewscentral) 's Twitter Profile Photo

“Physician motivation is the biggest driver of successful #ClinicalTrials in community oncology." Bilal Abid, MD, MS outlines how volume, access, staff, & tech-enabled platforms are reshaping trial capacity. bit.ly/4jWKhP4 #COA2025 Community Oncology UTHealth Houston News

CIBMTR (@cibmtr) 's Twitter Profile Photo

Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/articl…